ENTA - CIK 0001177648
The table below shows ENANTA PHARMACEUTICALS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$19.27M | -$78.76M | -$103.15M | -$84.78M | -$70.00M | $7.09M |
| Capital expenditure | $12.90M | $17.95M | $9.06M | $2.13M | $750.00K | $1.45M |
| Investing cash flow | $40.35M | $58.23M | -$53.58M | $54.90M | $36.99M | $19.83M |
| Dividends paid | - | - | - | - | - | - |
ENANTA PHARMACEUTICALS INC reported operating cash flow of -$19.27M for fiscal year 2025. That is up 75.5% from -$78.76M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $35.81M (FY 2016) to -$19.27M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$26.62M | -$27.63M | $198.13M | $20.03M | $3.08M | $8.98M |